Type 1 Diabetes

Noninvasive scans of retinal thickness and vasculature may be used in risk assessment for cognitive dysfunction for adults with type 1 diabetes, according to study data.

Exercise modalities have varying effects in long-term glycemic response for adults with type 1 diabetes, and aerobic exercise may be the best approach to reduce the risk for delayed hypoglycemic events, according to study data.

A modified version of an FDA-approved close-loop insulin delivery system may be effective for children aged 2 to 5 years with type 1 diabetes, according to study data published in Diabetes Technology & Therapeutics.

The FDA cleared an investigational new drug application for VX-880, a stem cell-derived therapy for patients with type 1 diabetes, according to the agent’s manufacturer.

Adults with type 1 diabetes had improvements in glycemic control after switching from an intermittently scanned continuous glucose monitor to a real-time CGM, according to a study published in Diabetes Technology & Therapeutics.

Non-Hispanic Black patients with COVID-19 and type 1 diabetes are more than three times more likely to be hospitalized for diabetic ketoacidosis compared with non-Hispanic white patients, according to study data.

Insulin pump and continuous glucose monitor use were lower among Black young adults with type 1 diabetes in the U.S. compared with their white and Hispanic peers after adjusting for socioeconomic status, according to study data.

Individuals with type 1 diabetes had lower mean glucose levels and spent more time in range on days they exercised compared with sedentary days, according to data published in Diabetes Technology & Therapeutics.

Individuals with type 1 diabetes and those with type 2 diabetes have similar increased risks for COVID-19 hospitalization and severe illness compared with those without diabetes, according to a study published in Diabetes Care.

A cohort of adults with type 1 diabetes in Spain had a decrease in mean glucose during the country’s COVID-19 lockdown, with about 17% of the group having clinically meaningful glycemic improvement, according to study data.